Scholar Rock Shares Gain After Removing Novo Nordisk Plant From FDA Filing

Scholar Rock De-Risks Regulatory Pathway for Lead Candidate

Scholar Rock ($SRRK) shares soared on Tuesday after the biotechnology firm confirmed it had removed a specific Catalent manufacturing facility, recently acquired by Novo Nordisk, from its Biologics License Application (BLA) for its lead investigational candidate, apitegromab. The strategic update, disclosed after market close on Monday, signals a significant de-risking of the regulatory process for the novel treatment targeting spinal muscular atrophy (SMA).

Immediately following the news, $SRRK stock surged 28.5% to close at $12.18, with trading volume spiking to over 8.7 million shares, nearly five times its 30-day average. The positive market reaction underscored investor relief that a potential bottleneck in the approval process for apitegromab, previously linked to manufacturing concerns at the Catalent plant, appears to have been mitigated.

Market Impact

Scholar Rock's robust performance on Tuesday positioned it as one of the top gainers in the biotechnology sector, adding approximately $180 million to its market capitalization, which now stands at $810 million. The stock’s ascent to $12.18 represents its highest closing price since September 2023 and marks its largest single-day percentage gain since July 2022, when it reported positive Phase 2 data for apitegromab. This significant move signals a strong shift in investor sentiment, moving past previous anxieties surrounding manufacturing compliance.

The Catalent facility in question, located in Bloomington, Indiana, has faced scrutiny from the U.S. Food and Drug Administration (FDA) in recent years, including several Form 483 observations related to quality control and manufacturing practices. These regulatory concerns have historically caused delays or complicated approval processes for drugs relying on production from such sites. By proactively addressing this, Scholar Rock has effectively removed a substantial overhang on its BLA submission. The positive sentiment could also spill over to other small-cap biotechs that have been similarly impacted by third-party contract manufacturing organization (CMO) issues, potentially suggesting that proactive risk mitigation can unlock significant value. However, the unique circumstances of each company's CMO relationship mean broad sector-wide impacts are likely limited beyond a general boost in confidence for de-risking strategies.

What Analysts Are Saying

Analysts widely applauded Scholar Rock's decisive action, with several firms reiterating or upgrading their outlooks on the stock. "Scholar Rock’s decision to remove the problematic Catalent site from its BLA filing for apitegromab is a critical de-risking event," stated Dr. Emily Chen, a senior biotechnology analyst at Evercore ISI, in a client note issued Tuesday. "This move directly addresses a key regulatory concern that had cast a shadow over the program's timeline and approval prospects. We are maintaining our 'Outperform' rating and raising our price target to $18 from $15, reflecting increased confidence in a timely approval."

Similarly, Leerink Partners analyst Michael Kim noted, "The market has long been concerned about the manufacturing readiness for apitegromab, particularly given the FDA's heightened scrutiny on CMO facilities. Scholar Rock has demonstrated proactive risk management, which should expedite the BLA review process and bring apitegromab closer to patients with SMA. We see a clear path to market now and believe the current valuation does not fully reflect apitegromab's peak sales potential, which we estimate at over $1 billion annually."

However, some analysts maintained a more cautious stance, emphasizing execution risks. "While the removal of the Catalent site is undoubtedly positive, Scholar Rock must now demonstrate seamless integration with its new manufacturing partner and ensure no new issues arise," cautioned Dr. Robert Hayes, an analyst at Raymond James. "The FDA's review process remains rigorous, and any new manufacturing hiccups could still delay approval. We maintain our 'Market Perform' rating for now, pending further clarity on the revised BLA submission and the new manufacturing strategy."

What to Watch

Investors will closely monitor several key catalysts and data points in the coming months following Scholar Rock's decisive manufacturing change. The most immediate watch point is the company's formal resubmission of its Biologics License Application (BLA) for apitegromab, which is now expected in late Q3 2024. This revised submission will trigger a new PDUFA (Prescription Drug User Fee Act) goal date, typically within six to ten months, providing a clearer timeline for a potential FDA approval decision.

Beyond the BLA resubmission, investors should track Scholar Rock's financial health and any updates regarding its commercialization strategy for apitegromab. The company's next earnings call, tentatively scheduled for early November, will offer an opportunity for management to provide further details on its manufacturing partners, supply chain stability, and market preparation efforts. Key price levels to watch include the immediate resistance at $13.50, a level last seen in early 2023, with strong support forming around $10.80 following Tuesday's surge.

Risk factors that could temper the current bullish momentum include unforeseen manufacturing challenges with the new CMO, potential delays in the FDA's review of the revised BLA, or the emergence of new competitive therapies in the SMA landscape. Additionally, any broader market downturns or shifts in investor appetite for high-growth biotechnology stocks could also impact $SRRK's performance, regardless of its operational progress.